CKD患者时变eGFR变异性与死亡、心血管疾病及终末期肾病的关联:CRIC研究
该回顾性队列研究纳入4,224例eGFR 20-70mL/min/1.73m2的CKD患者,以连续3次年度随访eGFR计算的变异系数为暴露,并每年滑动更新。时变模型显示eGFR变异性每增加1个标准差与心血管疾病、终末期肾病和全因死亡风险显著相关,关联强于基线单次窗口模型。
要点
- 时变eGFR变异性与CKD患者心血管疾病、终末期肾病和死亡风险独立相关。
- 时变模型关联强度显著大于基线单次测定窗口模型。
- 关联独立于eGFR绝对水平和eGFR斜率。
核心结论
- 时变eGFR变异性与心血管疾病、终末期肾病和全因死亡风险独立相关,且关联强于单次测定窗口的eGFR变异性。
研究设计与样本
- 回顾性队列研究,纳入慢性肾功能不全队列研究(CRIC)中eGFR 20-70mL/min/1.73m2的4,224例参与者。
- 暴露为基于连续3次年度随访eGFR计算的变异系数,从基线开始并以1年滑动窗口重复更新。
主要发现
- 基线模型中eGFR变异性每增加1个标准差,心血管疾病风险增加1.04倍(95%CI 0.96-1.13),无统计学显著性。
- 时变模型中eGFR变异性每增加1个标准差,心血管疾病风险增加3.34倍(95%CI 2.33-4.79)。
- 基线模型中eGFR变异性每增加1个标准差,终末期肾病风险增加1.08倍(95%CI 0.99-1.18),无统计学显著性。
- 时变模型中eGFR变异性每增加1个标准差,终末期肾病风险增加5.97倍(95%CI 3.74-9.52)。
- 基线模型中eGFR变异性每增加1个标准差,全因死亡风险增加1.15倍(95%CI 1.08-1.23);时变模型中增加1.52倍(95%CI 1.19-1.94)。
临床怎么用
- 在CKD随访中动态评估eGFR变异性,而非仅依赖基线单次窗口,可能有助于识别心血管疾病、终末期肾病和死亡高风险患者。
局限性
- 存在残余混杂。
- 研究中eGFR检测间隔与真实临床实践存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Previous reports have identified increased estimated glomerular filtration rate (eGFR) variability, measured during a single ascertainment window, as a risk factor for cardiovascular disease and all-cause mortality. We hypothesized that repeated measures of eGFR variability that are time-updated would exhibit stronger associations with common chronic kidney disease outcomes compared with eGFR variability derived from a single ascertainment window. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: 4,224 participants in the Chronic Renal Insufficiency Cohort Study with an eGFR of 20-70mL/min/1.73m2. EXPOSURE: Variability of eGFR was defined as the coefficient of variation calculated based on measures at 3 consecutive annual follow-up visits, starting at baseline and time-updated repeatedly in 1-year sliding windows. OUTCOME: Cardiovascular disease, end-stage kidney disease, and death. ANALYTICAL APPROACH: Cox proportional hazards models that included baseline covariates and eGFR variability measured during the first ascertainment window (baseline model) and marginal structural models that included repeated measures of eGFR variability and covariates (time-updated model). RESULTS: In the baseline and time-updated multivariable adjusted analyses, each standard deviation increase in eGFR rate variability was associated with a respective 1.04-fold (95% CI, 0.96-1.13) and 3.34-fold (95% CI, 2.33-4.79) increased risk of cardiovascular disease, 1.08-fold (95% CI, 0.99-1.18) and 5.97-fold (95% CI, 3.74-9.52) increased risk of end-stage kidney disease, and 1.15-fold (95% CI, 1.08-1.23) and 1.52-fold (95% CI, 1.19-1.94) increased risk of all-cause mortality. LIMITATIONS: Residual confounding and differences in eGFR intervals from real-world clinical practice. CONCLUSIONS: Variability in eGFR over time is independently associated with risks of cardiovascular and kidney outcomes and mortality, even after accounting for the absolute level of eGFR and eGFR slope. PLAIN-LANGUAGE SUMMARY: Estimated glomerular filtration rate (eGFR) is a key indicator of kidney function calculated from routine clinical blood test results. It is well established that variability in eGFR over time is associated with poor patient outcomes such as mortality. However, previous analyses have primarily focused on the relationship between the initial eGFR variability observed and future adverse events. In this study, we continuously updated eGFR variability over time and analyzed its association with the development of cardiovascular disease, end-stage kidney disease, and mortality. Our findings demonstrated a stronger association between time-updated eGFR variability and these outcomes compared with the previous analytical methods.
引用
- Nishiwaki H, Missikpode C, Ricardo AC, et al. Time-Updated Estimated GFR Variability Is Associated With Mortality, Cardiovascular Disease, and End-Stage Kidney Disease in Patients With CKD: Findings From the CRIC Study. Am J Kidney Dis. 2025. PMID: 40054592. doi:10.1053/j.ajkd.2025.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。